Feldmann Marc
Kennedy Institute of Rheumatology Division, Imperial College London, London W6 8LH, UK.
Annu Rev Immunol. 2009;27:1-27. doi: 10.1146/annurev-immunol-082708-100732.
Autoimmunity and the pathogenesis of autoimmune diseases were a major focus of the Walter and Eliza Hall Institute, where I started my research career. After my initial studies on immune cell culture and immune regulation, I returned to an analysis of the pathogenesis of human autoimmunity in London. Linking upregulated antigen presentation to autoimmunity led to an investigation of the role of cytokines in rheumatoid arthritis (RA), in collaboration with Ravinder Maini. These experiments defined the concept of a TNF-dependent cytokine cascade driving the manifestations of RA, which led to successful clinical trials of anti-TNF monoclonal antibody in RA patients, heralding a major change in medical practice. This success was made possible by enthusiastic support from many laboratory and clinical colleagues and taught us that cytokines are important rate-limiting steps and hence good therapeutic targets. My current scientific challenge is exploring the hypothesis of whether all major medical needs can be approached via cytokine blockade.
自身免疫及自身免疫性疾病的发病机制是沃尔特与伊丽莎·霍尔研究所的主要研究重点,我就是在那里开启了自己的研究职业生涯。在对免疫细胞培养和免疫调节进行初步研究后,我回到伦敦,继续分析人类自身免疫的发病机制。将上调的抗原呈递与自身免疫联系起来,促使我与拉温德·梅尼合作,研究细胞因子在类风湿关节炎(RA)中的作用。这些实验明确了驱动RA症状的肿瘤坏死因子(TNF)依赖性细胞因子级联反应的概念,进而促成了抗TNF单克隆抗体在RA患者中的成功临床试验,开创了医学实践的重大变革。众多实验室和临床同事的热情支持使这一成功成为可能,也让我们认识到细胞因子是重要的限速步骤,因此是良好的治疗靶点。我目前面临的科学挑战是探究是否所有重大医疗需求都可通过细胞因子阻断来解决这一假设。